Seres Therapeutics (MCRB) Posts Q2 Loss of $1.45/Share

Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($1.45), $1.15 worse than the analyst estimate of ($0.30).

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Super Micro Computer rises on AI server market optimism
• JPMorgan Downgrades Shanghai Chicmax Cosmetic (2145:HK) to Neutral